Francesco Sinigaglia becomes Chairman at Eyevensys

Raffy Kazandjian is Chief Executive at the French ophthalmic company

Eyevensys, a French ophthalmic therapy company located in Paris, has appointed Francesco Sinigaglia as Chairman of the Board of Directors.

Sinigaglia is a senior pharma professional and entrepreneur. He is currently a member of the Executive Board of Dompé, and founder and Chief Operating Officer of Anabasis, a biotech company specialising in the development of innovative therapies for the eye that was acquired by the Dompé Group in 2012.

He has more than 30 years of industry experience in the healthcare sector, in particular at Roche headquarters in Basel, Switzerland. In 2002 he co-founded Bioxell, a biotech company he led for eight years and took to the Zurich stock exchange in 2006.

Sinigaglia joins the Eyevensys Board members Chahra Louafi (Bpifrance Investissement); Cécile Tharaud (Inserm Transfert Initiative); Catherine Boulé (CapDecisif Management); Caroline Boukris (independent); Frank Kalkbrenner (BIVF); and Raffy Kazandjian, who is the company's Chief Executive.

You may also like

Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Subscribe now